Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Dec 23;8(2):e001689. doi: 10.1136/jitc-2020-001689

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Levels of serum CD73 activity within 3 months therapy with anti-PD-1 agents. A, Levels of serum CD73 activity at time points pretreatment (0) and on-treatment (3 months) in all patients analyzed (n=60). B, Comparison of serum CD73 activity in patients with or without clinical benefits to nivolumab or pembrolizumab at time points pretreatment (0) and on-treatment (3 months). Mean±SD is shown. P values were calculated with the two-way analysis of variance (B). CR, complete response; PD-1, programmed cell death protein 1; PD, progressive disease; Pi, inorganic phosphate; PR, partial response; SD, stable disease.